Vivax Working Group Annual Meeting 2017

9-11 October 2017Bali – Indonesia

The APMEN VxWG Annual Meeting 2017 was held in Bali, Indonesia in collaboration with the Malaria in Pregnancy Consortium. This year’s meeting was hosted back to back with the Medicines for Malaria Venture (MMV) stakeholder meeting.

The Annual meeting drew more than 110 participants representing 18 APMEN Country Partners and Partner Institutions, along with active participation from other observers in attendance. The Vivax working group meeting brought together key stakeholders from National Malaria Control Programs, policy makers, healthcare providers, academics, funders and the World Health Organisation to  work together to generate solutions to overcome a parasite with a known ability to evade its demise.

Download the agenda


Day One - Tackling Effective Radical Cure of P. vivax

Session 1: Welcome and Overview

Session 2: Tackling Adherence

  • Discussion and feedback

Session 3: Research Methods

Session 4: Gathering the Evidence

  • Discussion and feedback

Day Two – Malaria in Pregnancy

Session 1: Burden and Treatment of falciparum and vivax malaria in pregnancy

  • Introductions and Overview of MiP trials and other studies in Asia/Pacific – Paul Pronyk
  • Burden and impact of Plasmodium falciparum and P. vivax in pregnancy, with a focus on the Asia/Pacific region – Azucena Bardaji
  • Safety and efficacy of ACTs and quinine for treatment of malaria in 1st, and 2nd and 3rd trimester pregnancy, and implications for national policy – Feiko ter Kuile
  • A Phase II/III randomised clinical trial of the efficacy and safety of artesunate + sulphadoxine-pyrimethamine, and artesunate + mefloquine to treat uncomplicated falciparum malaria in pregnancy in India – Anup Anvikar 
  • Discussion and feedback on Treatment of MiP

Session 2: Prevention of falciparum and vivax malaria in pregnancy

  • Intermittent preventive treatment of 3 courses of sulphadoxine-pyrimethamine plus azithromycin twice daily for two days compared to SP plus chloroquine (three days) for prevention of low birthweight in Papua New Guinea – Stephen Rogerson
  • RCT on the efficacy and safety of intermittent screening and treatment (IST) with AS+SP versus passive case detection in India – Daniel Chandramohan
  • Rationale for STOPMiP trial in Indonesia & assessment of the performance of RDTs for screening malaria in pregnancy – Rukhsana Ahmed
  • Results of intermittent Screening and Treatment or Intermittent Preventive Therapy with DP versus single screening and treatment in pregnancy and on infant outcomes in Indonesia – Rini Poespoprodjo
  • Evaluation of single screening and treatment (SST, current policy), acceptability and cost-effectiveness of ISTp or IPTp with DP versus SST of malaria in Indonesia – Rukhsana Ahmed

Session 3: Round table discussions on Prevention of MiP

  • Discussion and feedback
  • Summary 1 & 2

Day Three – Vivax Working Group Business Meeting

Session 1: Workplan

Session 2: House Keeping

  • Discussion and feedback on Breakout Discussions